Institute Goals and Overview

Institute Overview

AACAP’s 2017 Pediatric Psychopharmacology Update Institute, Psychopharmacology Treatments from Childhood Through Transitional Age, links in these age groups the latest findings on the treatment of attention-deficit/hyperactivity disorder (ADHD), bipolar and depressive disorders, eating disorders, psychosis and schizophrenia, autism spectrum disorders, pediatric autoimmune neuropsychiatric disorders (PANS and PANDAS), and prodromal and high risk mood and psychotic disorders.

Eight top child and adolescent psychiatric researchers detail their approaches to treatment of psychiatric disorders from preschool through transitional age youth with the latest psychiatric medications, discussing medication selection, effectiveness, and expected adverse events. They review the latest data that address the balance of benefit to risk across this age range using first-line psychotropic medications, in the treatment of youth. In addition to known best evidence, including FDA-approved treatments, the speakers describe other relevant treatments that work in conjunction with psychotropic medication.

At the end of the Institute, clinicians will have thoroughly reviewed current publications on psychopharmacologic treatments across the age range targeted so they can discuss how efficacy, safety, and outcome data is translated into clinical practice.

Educational Learning Objectives

At the conclusion of this CME activity, the participant will be able to:

  1. Discuss the latest evidence-based psychopharmacology data that specify indication and adverse events for medication treatment for important psychiatric disorders from preschool through young adulthood with stimulant medications, second generation antipsychotic medications, lithium, and selective serotonin reuptake inhibitors.
  2. List the first- and second-line psychopharmacological medication choices and dose ranges for youth who present with ADHD, depressive disorders, bipolar disorders, eating disorders, autism spectrum disorders, psychosis, and children with prodromal or at high risk for mood and psychotic disorders.
  3. Present the starting doses of pediatric psychopharmacological agents, their titration plans, how long a medication needs to be tried before switching to another medication, and the methods of phasing in a new medication while withdrawing the other, especially regarding patients at different ages.
  4. List the barriers that mitigate against the successful treatment with psychiatric medications for children, adolescents, and young adults with psychiatric disorders, as well as possible solutions, including those that may not require the use of medication.